Citations

Clear

815 citation(s) found for "Tang, Yu".

Network-Based Integration of GWAS and Gene Expression Identifies a HOX -Centric Network Associated with Serous Ovarian Cancer Risk
Kar, Siddhartha , Lawrenson, Kate , Aben, Katja K.H. , Antonenkova, Natalia, Chenevix‐Trench, Georgia , Study, on behalf of the Australian Cancer, Group, and on behalf of the Australian Ovarian Cancer Study, Baker, Helen , Bean, Yukie T., Beckmann, Matthias W. , Bisogna, Maria, Bogdanova, Natalia , Brinton, Louise A. , Campbell, Ian , Carty, Karen , Chang‐Claude, Jenny , Chen, Y. Ann , Chen, Zhihua , Cunningham, Julie M. , Dansonka‐Mieszkowska, Agnieszka , Dicks, Ed , Dörk, Thilo , Eccles, Diana , Easton, Douglas F. , Edwards, Robert P., Ekici, Arif B. , Fasching, Peter A. , Gao, Yu‐Tang , Giles, Graham G. , Glasspool, Rosalind , Goode, Ellen L. , Goodman, Marc T. , Grownwald, Jacek, Harrington, Patricia, Harter, Philipp , Hein, Alexander , Heitz, Florian , Hildebrandt, Michelle A.T., Hillemanns, Peter , Høgdall, Estrid , Høgdall, Claus , Hosono, Satoyo , Iversen, Edwin S., Jakubowska, Anna , Jensen, Allan , Ji, Bu‐Tian , Kjær, Susanne K. , Kelemen, Linda E. , Kellar, Melissa, Kelley, Joseph L., Kiemeney, Lambertus A. , Krakstad, Camilla , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lambrechts, Sandrina, Le, Nhu D. , Lee, Alice W. , Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A. , Liang, Dong , Lissowska, Jolanta , Lu, Karen, Lubiński, Jan , Lundvall, Lene, Massuger, Leon F.A.G. , Matsuo, Keitaro , McGuire, Valerie , McLaughlin, John R., McNeish, Iain A. , Menon, Usha , Moysich, Kirsten B., Narod, Steven A., Nedergaard, Lotte , Ness, Roberta B., Odunsi, Kunle , Olson, Sara H. , Orlow, Irene , Oršulić, Sandra , Weber, Rachel Palmieri , Pearce, Celeste Leigh, Pelttari, Liisa M. , Permuth‐Wey, Jennifer, Phelan, Catherine M., Pike, Malcolm C., Ramus, Susan J. , Rossing, Mary Anne, Rothstein, Joseph H. , Runnebaum, Ingo B. , Rzepecka, Iwona K. , Salvesen, Helga B., Schildkraut, Joellen M. , Schwaab, Ira, Shvetsov, Yurii B. , Sieh, Weiva , Song, Honglin , Southey, Melissa C. , Sucheston‐Campbell, Lara, Tangen, Ingvild L. , Teo, Soo‐Hwang , Terry, Kathryn L. , Thompson, Pamela J., Timorek, Agnieszka, Tworoger, Shelley S. , Altena, Anne M. van , Nieuwenhuysen, Els Van , Vergote, Ignace , Vierkant, Robert A. , Wang‐Gohrke, Shan , Walsh, Christine , Wentzensen, Nicolas, Whittemore, Alice S. , Wicklund, Kristine G. , Woo, Yin Ling , Wu, Xifeng , Wu, Anna H. , Zheng, Wei , Sellers, Thomas A. , Monteiro, Álvaro N.A. , Freedman, Matthew L., Gayther, Simon A. , Lu, Karen H. , Lambrechts, Diether , Tyrer, Jonathan P. , Li, Qiyuan , Anton‐Culver, Hoda , Study, on behalf of the Australian Cancer, Group, and on behalf of the Australian Ovarian Cancer Study, Bandera, Elisa V. , Berchuck, Andrew , Bjørge, Line , Brooks‐Wilson, Angela , Bützow, Ralf C. , Cook, Linda S. , Cramer, Daniel W. , Cybulski, Cezary , Dennis, Joe , Doherty, Jennifer A. , Bois, Andreas du , Dürst, Matthias , Fridley, Brooke L. , Gentry‐Maharaj, Aleksandra , Hildebrandt, Michelle A.T. , Paul, James , Karlan, Beth Y. , Lu, Karen, McLaughlin, John R., Modugno, Francesmary , Nevanlinna, Heli , Pejovic, Tanja B. , Poole, Elizabeth M. , Risch, Harvey A. , Rosen, Barry P. , Rudolph, Anja , Shu, Xiao‐Ou , Siddiqui, Nadeem , Wentzensen, Nicolas , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Pharoah, Paul D.P. , Pelttari, L M , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , Kiemeney, Lambertus A , Kjaer, Susanne K , McNeish, Iain A , Ramus, Susan J , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Monteiro, Alvaro N , Moysich, Kirsten , Orlow, Irene , Lissowska, Jolanta , Campbell, Ian G , Southey, Melissa C , Glasspool, Rosalind , Matsuo, Keitaro , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Zheng, Wei , Høgdall, Estrid , Høgdall, Claus K , Kar, Siddhartha , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 24, 2015 | Volume: 24 | Issue: 10 | Pages: 1574-1584

10.1158/1055-9965.epi-14-1270 | PMID 26209509 Get It

Abstract Background: Genome-wide association studies (GWAS) have so far reported 12 loci associated with serous epithelial ovarian cancer (EOC) risk. We hypothesized that some of these loci function through nearby transcription factor (TF) genes and that putative target genes of these TFs as identified by coexpression may also be enriched for additional EOC risk associations. Methods: We selected TF genes within 1 Mb of the top signal at the 12 genome-wide significant risk loci. Mutual information, a form of correlation, was used to build networks of genes strongly coexpressed with each selected TF gene in the unified microarray dataset of 489 serous EOC tumors from The Cancer Genome Atlas. Genes represented in this dataset were subsequently ranked using a gene-level test based on results for germline SNPs from a serous EOC GWAS meta-analysis (2,196 cases/4,396 controls). Results: Gene set enrichment analysis identified six networks centered on TF genes (HOXB2, HOXB5, HOXB6, HOXB7 at 17q21.32 and HOXD1, HOXD3 at 2q31) that were significantly enriched for genes from the risk-associated end of the ranked list (P < 0.05 and FDR < 0.05). These results were replicated (P < 0.05) using an independent association study (7,035 cases/21,693 controls). Genes underlying enrichment in the six networks were pooled into a combined network. Conclusion: We identified a HOX-centric network associated with serous EOC risk containing several genes with known or emerging roles in serous EOC development. Impact: Network analysis integrating large, context-specific datasets has the potential to offer mechanistic insights into cancer susceptibility and prioritize genes for experimental characterization. Cancer Epidemiol Biomarkers Prev; 24(10); 1574–84. ©2015 AACR.
Substantial Neuroprotective and Neurite Outgrowth-Promoting Activities by Bis(propyl)-cognitin via the Activation of Alpha7-nAChR, a Promising Anti-Alzheimer’s Dimer
Hu, Shengquan, Cui, Wei , Mak, Shinghung , Xu, Daping , Y, Hu , Tang, Jing , Choi, Chung‐Lit, Lee, Mingyuen, Pang, Yuan‐Ping , Han, Yifan , Pang, Yuanping, Lee, Mingyuen, Han, Yifan , Pang, Yuan-Ping

Mayo Clinic

ACS Chemical Neuroscience | July 6, 2015 | Volume: 6 | Issue: 9 | Pages: 1536-1545

10.1021/acschemneuro.5b00108 | PMID 26147504 Get It

Inflammation negatively regulates FOXP3 and regulatory T-cell function via DBC1
Gao, Yayi , Tang, Jiayou , Li, Qiang , Nie, Jia , Lin, Fang , Wu, Qingsi, Chen, Zuojia , Gao, Zhimei, Fan, Huimin , Tsun, Andy , Shen, Jijia, Chen, Guihua , Liu, Zhongmin , Olsen, Nancy J. , Zheng, Song Guo , Li, Bin , Chen, Weiqian , Lou, Zhenkun

Mayo Clinic

Proceedings of the National Academy of Sciences | June 10, 2015 | Volume: 112 | Issue: 25 | Pages: No page available

10.1073/pnas.1421463112 | PMID 26060310 Get It

Significance Treg cells suppress excessive and aberrant immune responses. Impaired function or homeostasis of Treg cells would induce severe autoimmune and inflammatory diseases. Forkhead box P3 (FOXP3), as a master regulator of Treg cells, forms a large complex with other binding factors to modulate Treg-cell function subtly in pathological and physiological conditions. We identified that Deleted in breast cancer 1 (DBC1) is an essential subunit of the FOXP3 complex in human CD4 + Treg cells. Our results show that the inflammatory cytokines TNF-α or IL-6 trigger FOXP3 degradation, whereas downregulation of DBC1 expression prevents FOXP3 degradation and maintains Treg-cell function under inflammatory stimuli in vitro and in vivo. These findings unveil a previously unidentified pathway for therapeutically modulating FOXP3 + Treg-cell stability under inflammation.
Trans‐Ethnic Meta‐Analysis Identifies Common and Rare Variants Associated with Hepatocyte Growth Factor Levels in the Multi‐Ethnic Study of Atherosclerosis (MESA)
Berardi, Cecilia , Decker, Paul A. , Wassel, Christina L. , Kirsch, Phillip S., Pankow, James S. , Sale, Michèle M. , Andrade, Mariza de , Sicotte, Hugues , Tang, Weihong , Hanson, Naomi Q., Tsai, Michael Y. , Bielinski, Suzette J. , de Andrade, Mariza, Larson, Nicholas B. , Decker, Paul A. , Taylor, Kent D. , de Andrade, Mariza , Bielinski, Suzette , Pankow, James S , Tang, Weihong

Mayo Clinic

Annals of Human Genetics | May 22, 2015 | Volume: 79 | Issue: 4 | Pages: 264-274

10.1111/ahg.12119 | PMID 25998175 Get It

SummaryHepatocyte growth factor (HGF) is a mesenchyme‐derived pleiotropic factor that regulates cell growth, motility, mitogenesis, and morphogenesis in a variety of cells, and increased serum levels of HGF have been linked to a number of clinical and subclinical cardiovascular disease phenotypes. However, little is currently known regarding which genetic factors influence HGF levels, despite evidence of substantial genetic contributions to HGF variation. Based upon ethnicity‐stratified single‐variant association analysis and trans‐ethnic meta‐analysis of 6201 participants of the Multi‐Ethnic Study of Atherosclerosis (MESA), we discovered five statistically significant common and low‐frequency variants: HGF missense polymorphism rs5745687 (p.E299K) as well as four variants (rs16844364, rs4690098, rs114303452, rs3748034) within or in proximity to HGFAC. We also identified two significant ethnicity‐specific gene‐level associations (A1BG in African Americans; FASN in Chinese Americans) based upon low‐frequency/rare variants, while meta‐analysis of gene‐level results identified a significant association for HGFAC. However, identified single‐variant associations explained modest proportions of the total trait variation and were not significantly associated with coronary artery calcium or coronary heart disease. Our findings indicate that genetic factors influencing circulating HGF levels may be complex and ethnically diverse.
Abstract 5592: Molecular classification of triple negative breast cancer via RNA-sequencing data
Sun, Zhifu, Sicotte, Hugues , Vedell, Peter T. , Barman, Poulami , Passow, Jeanette E. Eckel, Wieben, Eric D. , Wang, Liewei , Weinshilboum, Richard, Thompson, Kevin J. , Tang, Xiaojia , Sinnwell, Jason P. , Mahoney, Douglas W. , Hart, Steven N. , Ingle, James N. , Boughey, Judy C. , Kalari, Krishna R. , Goetz, Matthew P.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 5592-5592

10.1158/1538-7445.am2014-5592 Get It

Abstract Introduction: Triple negative breast cancers (TNBC) are characterized as lacking estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression and TNBC patients have higher rates of recurrence and death compared with other breast cancer subtypes. For TNBC patients who fail standard chemotherapy, there are a lack of novel drug therapies, given the absence of well-defined molecular targets. Recently, a microarray meta-analysis identified 7 triple negative subtypes, including the validation of the luminal androgen receptor (LAR) positive subtype [Lehmann, 2011]. However, microarray technology is dependent on probe-target specificity and the 7 subtypes have yet to be validated using RNA sequencing data, and the presences of recurrent genomic alterations in the 7 subtypes are unknown. METHODS: We obtained 1106 breast cancer RNA-Seq bam files from The Cancer Genome Atlas (TCGA) and aligned with Tophat v1.3. The PAM50 intrinsic gene signature was used to extract a cohort of 128 TNBC samples. Consensus clustering of genes, greater than 75th percentile of variance, was performed using Kmeans clustering in Spearman's correlation space. A nearest centroid prediction model was developed from genes differentially expressed among the clusters. Eighty independent TNBC RNA sequencing samples were obtained (British Colombia; BC) [Shah, 2012] which were calibrated to our TNBC conditional quantile normalized cohort and sub-typed by our model. RESULTS: Using RNA-Seq gene expression count data, we identified 5 clusters, all of which were stable, including the LAR cluster. Signaling pathway impact analysis (SPIA) implicated cytokine-cytokine receptor interaction, leukocyte transendothelial migration, and regulation of actin cytoskeleton pathways commonly altered in the non-LAR TNBC subtypes. In contrast, cell cycle, ECM-receptor interaction, endocrine regulated calcium reabsorption, and insulin signaling pathways were altered in the LAR versus non-LAR subtypes. Neuroactive ligand-receptor interactions were observed to be altered commonly between all sub-types. We then applied our model to the Shah, et al cohort. In this cohort, the LAR subtype was consistent with Shah's classification of ‘other’ TNBC and contained no basal samples by PAM50 intrinsic modeling. Analysis of sub-type specific mutation data from the BC cohort demonstrates an increased mutational load in ECM-related proteins, particularly the myosins, along with increased TP53 clonality in the non-LAR subtypes. CONCLUSIONS: Using TCGA RNASeq data, we have confirmed the presence of 5 major TNBC subtypes, including the LAR; which was negligible in basal composition by PAM50 intrinsic modeling. SPIA pathway analysis indicates a core set of pathways demonstrating altered expression across the TNBC sub-types and the identification of molecular targets within each subtype is ongoing. Citation Format: Kevin J. Thompson, Xiaojia Tang, Zhifu Sun, Jason P. Sinnwell, Hugues Sicotte, Douglas W. Mahoney, Steven Hart, Peter T. Vedell, Poulami Barman, Jeanette E. Eckel Passow, Eric D. Wieben, James N. Ingle, Judy C. Boughey, Liewei Wang, Richard Weinshilboum, Krishna R. Kalari, Matthew P. Goetz. Molecular classification of triple negative breast cancer via RNA-sequencing data. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5592. doi:10.1158/1538-7445.AM2014-5592
Abstract 4185: Analysis of sequencing data to identify potential drug targets for an individual newly diagnosed with basal breast cancer who failed to respond to current standard neoadjuvant chemotherapy
Barman, Poulami , Sicotte, Hugues , Vedell, Peter T. , Dockter, Travis , Jones, Katie N., Conners, Amy Lynn , Moyer, Ann M. , Visscher, Daniel W., Gao, Bowen , McLaughlin, Sarah A., Copland, John A. , Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Passow, Jeanette E. Eckel, Kocher, Jean‐Pierre , Wieben, Eric D. , Farrugia, Gianrico , Schultz, Cloann G. , Weinshilboum, Richard, Wang, Liewei , Kalari, Krishna R. , Tang, Xiaojia , Thompson, Kevin J. , Mahoney, Douglas W. , Sinnwell, Jason P. , Hart, Steven N. , Yu, Jia Xin , Suman, Vera J. , Ingle, James N. , Goetz, Matthew P. , Boughey, Judy C.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 4185-4185

10.1158/1538-7445.am2014-4185 Get It

Abstract INTRODUCTION Next generation sequencing (NGS) of patients has significantly changed our ways to study cancer genomics as it provides precise estimates of gene expression, fusion transcripts, expressed single nucleotide variants (eSNVs), splice variants and copy number variants. The Breast Cancer Genome Guided Therapy (BEAUTY) is an ongoing clinical study in which RNA sequencing (RNAseq) and whole exome sequencing (WES) are performed prior to, during and after neoadjuvant chemotherapy. Here we report the use of these sequencing technologies to investigate gene expression levels and mutational profiles in a triple negative breast cancer (TNBC) patient enrolled in BEAUTY whose disease did not respond to neoadjuvant paclitaxel and anthracycline/cycphosphamide. METHODS Computational approaches were used to integrate WES and RNAseq data obtained before therapy (V1T), after 12 weekly paclitaxel treatments (V2T) and after anthracycline-based regimen at surgical resection (V3T) to study a single patient with persistent TNBC disease after neoadjuvant chemotherapy. RESULTS Using RNA-Seq data, we identified an inter-chromosomal fusion transcript between chromosome 20 and 22 (GNAS-TTC38) that was highly expressed at V1T, V2T and V3T. We also identified intra-chromosomal fusion transcripts that were expressed at two time points, such as fusion transcript (KANSL1-ARL17A) on chromosome 17 for V1T and V2T and fusion transcript (RBM12B-LINC00535) on chromosome 8 for V2T and V3T time points. Several gene expression changes were also observed. Gene expression analysis of V1T, V2T and V3T tumors was performed. Differential temporal gene expression profiles of 9884 genes that were significant and varying at different time points were obtained for pathway analysis. Pathway analysis of 9884 genes identified up regulation and down regulation of several transcription factors with a fold change of 2x or more. When compared to blood, DNA tumor and RNA-Seq data, we identified 81 common somatic eSNVs that were expressed in both V1T and V2T time points and we are in the process of investigating V3T data. We found alterations of key transporter domains (CD225, Coatamer_beta_C, DUF2435, Dynamitin, EI24, GLTP, LMF1, Porin_3, V-ATPase_C) in our V1T and V2T SNV data. Similar to gene expression analysis, we are in the process of obtaining the list of mutations at various time points to identify driver and passenger mutation candidate genes for this specific TNBC patient. CONCLUSIONS Our initial time-series analysis of eSNV, fusion transcripts and gene expression data demonstrate that intensive analysis for individual patients is feasible. Further investigation of drug transporters and transcription regulators may help develop personalized treatment strategies for patients with disease resistant to current regimens. Citation Format: Krishna R. Kalari, Xiaojia Tang, Kevin J. Thompson, Douglas W. Mahoney, Poulami Barman, Jason P. Sinnwell, Hugues Sicotte, Peter Vedell, Steven N. Hart, Travis J. Dockter, Katie N. Jones, Amy L. Conners, Ann M. Moyer, Daniel W. Visscher, Jia Yu, Bowen Gao, Sarah A. McLaughlin, John A. Copland, Alvaro Moreno-Aspitia, Donald W. Northfelt, Richard J. Gray, Vera J. Suman, Jeanette E. Eckel Passow, Jean-Pierre A. Kocher, Eric D. Wieben, Gianrico Farrugia, Cloann G. Schultz, James N. Ingle, Richard Weinshilboum, Matthew P. Goetz, Liewei Wang, Judy C. Boughey. Analysis of sequencing data to identify potential drug targets for an individual newly diagnosed with basal breast cancer who failed to respond to current standard neoadjuvant chemotherapy. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4185. doi:10.1158/1538-7445.AM2014-4185
Abstract PD3-3: Impact of neoadjuvant chemotherapy on the clonal composition of breast cancer
Barrett, Michael T. , McLaughlin, Sarah A., Moreno‐Aspitia, Alvaro , Moyer, Ann M. , Northfelt, Donald W. , Gray, Richard J. , Barman, Poulami , Vedell, Peter T. , Dockter, Travis , Jones, Katie, Felten, Sara J., Conners, Amy Lynn , Eckel‐Passow, Jeanette E. , Sicotte, Hughes, Yu, Jia , Visscher, Daniel W., Wieben, Eric D. , Schultz, Cloann G. , Liu, Minetta C. , Wang, Liewei , Weinshilboum, R., Goetz, Matthew P. , Kalari, Krishna R. , Suman, Vera J. , Sinnwell, Jason P. , Mahoney, Douglas W. , Tang, Xiaojia , Thompson, Kevin J. , Hart, Steven N. , Ingle, James N. , Boughey, Judy C.

Mayo Clinic

Cancer Research | May 4, 2015 | Volume: 75 | Issue: 9_Supplement | Pages: PD3-3-PD3-3

10.1158/1538-7445.sabcs14-pd3-3 Get It

Abstract Background Cancer genomic investigations have identified recurrent genomic aberrations critical for cancer initiation, progression, and metastases. However, these investigations are typically performed in isolation, and the effects of treatment on the clonal selection of tumor cells are mostly unknown. We hypothesized that molecular profiling of residual tumors after neoadjuvant chemotherapy (NAC) would identify new drug targets/pathways in patients at high risk for disease recurrence. To better identify clonal populations of resistant breast cancer cells, we utilized DNA content-based flow sorting of nuclei to identify and isolate clonal populations for aCGH and next generation sequencing (NGS) both before and after NAC. Methods The Breast Cancer Genome Guided Therapy Study (BEAUTY) (NCT 02022202) is a prospective study of patients with high-risk breast cancer treated with neoadjuvant 12 weekly paclitaxel (T) +/- trastuzumab followed by 4 cycles of anthracycline based chemotherapy. Tumor tissue from baseline, residual disease from surgery, distant metastases, and patient derived xenografts (PDX) are obtained for cell sorting by DNA ploidy, aCGH, RNA and exome sequencing. Results: 140 patients have been enrolled, 104 have completed surgery and 30 unique PDX have been established corresponding to 26 patients prior to chemotherapy and 4 from residual disease at surgery. Baseline exome and RNA sequencing is complete in 140. Currently, genomic analyses of flow sorted matched baseline, surgical, PDX, and distant disease samples are available in 6 patients. Substantial genomic variation was observed in the surgical sample compared to the primary tumor including gain of oncogenic drivers (EGFR) and loss of negative regulators (ATG5) (Table). The PDX recapitulated these events with excellent fidelity compared to the corresponding human tumor. In patients with TNBC, RNA seq obained from matched samples demonstrated changes in immune related pathways. Evaluation of drug targets/pathways identified in the resistant tumors are ongoing using the PDX and sequencing of the remaining matched baseline/surgical disease will be reported. Clonal changes occurring over time in patients with residual disease or disease recurrence after NACTumor SubtypeResidual Cancer BurdenDisease StatusClonal Aberration Changes (baseline and post NAC)TNBC (AR subtype)3Contralateral lymph node recurrence at 150 days2p25.2 - p25.1 amplicon lost at recurrence; 6p21.32 -p21.31 amplicon lost at recurrenceTNBC (BL 1)3Bone/liver/lymph node recurrence at 135 days5q11.2 amplicon gained at surgery; 12p13.33 - p13.2 amplicon gained at surgeryTNBC (BL 1)3Disease-free at day 1506q21 amplicon lost at sugeryTNBC (BL 2)0Brain recurrence at 390 daysChr 2 chromothripsis at surgeryLuminal B3Progression during chemotherapy7p12.1 - p11.2 amplicon gained at surgeryLuminal HER23Disease-free at day 3609q33.2 amplicon lost at surgery; 15q13.1 - q13.3 amplicon lost at surgery; 15q22.2 - q24.1 amplicon lost at surgery Conclusions: We observed substantial evolutionary changes in residual breast tumors remaining after NAC. Our findings suggest that a comprehensive assessment of the mutational landscape that has evolved during NAC can inform drug development in high risk breast cancer patients. Citation Format: Matthew P Goetz, Michael T Barrett, Krishna R Kalari, Vera J Suman, Sarah A McLaughlin, Alvaro Moreno-Aspitia, Ann M Moyer, Donald W Northfelt, Richard J Gray, Jason Sinnwell, Douglas Mahoney, Poulami Barman, Peter Vedell, Xiaojia Tang, Kevin Thompson, Travis Dockter, Katie Jones, Sara J Felten, Amy Conners, Jeanette Eckel-Passow, Hughes Sicotte, Steven N Hart, Jia Yu, Daniel W Visscher, Eric D Wieben, Cloann Schultz, Minetta C Liu, James N Ingle, Liewei Wang, Richard W Weinshilboum, Judy C Boughey. Impact of neoadjuvant chemotherapy on the clonal composition of breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr PD3-3.
Abstract A26: Attacking the most downstream “gatekeeper,” the SIAH-dependent proteolytic machinery, in the oncogenic ERBB/K-RAS signaling pathway to block tumorigenesis and control metastasis in human cancer
Bian, Minglei, Zheleva, Vasilena, Urban, Zena M., Njogu, Monicah M., Odanga, Justin J. , Isbell, Andrew J., Perry, Roger R , Smyrk, Thomas C. , Petersen, Gloria M. , Liao, Yang , Hoefer, Richard A. , Tang, Amy

Mayo Clinic

Molecular Cancer Research | May 4, 2015 | Volume: 12 | Issue: 12_Supplement | Pages: A26-A26

10.1158/1557-3125.rasonc14-a26 Get It

Abstract Oncogenic K-RAS activation is a major menace that drives aggressive tumor progression and metastasis in 30% of all human cancer. Currently, there are no effective therapies to treat stage III and IV metastatic human cancers with oncogenic K-RAS hyperactivation that often confer drug resistance, aggressive tumor growth, systemic metastasis, and poor clinical outcome. Therefore, finding novel approaches and new drug targets to inhibit oncogenic K-RAS pathway activation is an urgent goal and the major challenge in cancer therapy and anti-K-RAS-based drug development. Instead of targeting an upstream signaling module such as EGFR/HER2/K-RAS/B-RAF, we targeted the most downstream signaling module in the oncogenic K-RAS signaling pathway called the SIAH-dependent proteolytic machinery. SIAHs are the human homologs of Seven-In-Absentia (SINA), an evolutionarily conserved RING E3 ligase - the most downstream signaling module and a critical “gatekeeper” required for proper RAS signal transduction. Guided by the insights and fundamental principles learned from the Drosophila RAS signal transduction, we conducted preclinical studies to dissect SIAH function in promoting the oncogenic K-RAS-driven tumorigenesis and metastasis in human cancer. We found that (1) SIAH is a new biomarker reflective of oncogenic K-RAS activation in human cancer, and (2) SIAH loss-of-function is highly effective to block tumorigenesis and metastasis against the well-established, end-stage and metastatic pancreatic cancer and triple negative breast cancer (TNBC). These findings demonstrate that SIAH is an attractive and logical new therapeutic target for developing novel and effective anti-K-RAS and anticancer therapy against metastatic human cancer. Through our work, SIAH has emerged as a promising new drug target against oncogenic K-RAS hyperactivation in metastatic human cancer cells. Using anti-SIAH molecules to block oncogenic K-RAS signaling in human cancer is an excellent example of science going “from the bench (basic research in fruit flies) to the bedside (preclinical studies and ultimately clinical trials)”. As a highly evolutionarily conserved E3 ligase that is the most downstream and the most conserved “signaling gatekeeper” in the oncogenic K-RAS signaling network, SIAH is uniquely and strategically positioned to become a great and logical anti-K-RAS drug target. Our preclinical studies have demonstrated that “SIAH-dependent proteolysis” is indeed an Achilles' heel in metastatic human cancer cells. Knowledge gained from our preclinical study has promising translational values. Anti-SIAH-based small molecule inhibitors are likely to aid in expanding our limited arsenal of novel anti-K-RAS-based anticancer therapies. By attacking the oncogenic K-RAS pathway using multi-pronged synergistic inhibitions at upstream (EGFR/HER2 membrane receptors), midstream (K-RAS/B-RAF/MEK/mTOR) and downstream (SIAH E3 ligase) signaling modules in parallel, we will be in a position to control the late-stage, relapsed and metastatic human cancers by shutting down the hyperactivated K-RAS signaling transduction cascades in cancer cells in the future. Citation Format: Minglei Bian, Yang Liao, Vasilena Zheleva, Zena Urban, Monicah Njogu, Justin J. Odanga, Andrew J. Isbell, Roger R. Perry, Richard A. Hoefer, Thomas C. Smyrk, Gloria M. Petersen, Amy H. Tang. Attacking the most downstream “gatekeeper,” the SIAH-dependent proteolytic machinery, in the oncogenic ERBB/K-RAS signaling pathway to block tumorigenesis and control metastasis in human cancer. [abstract]. In: Proceedings of the AACR Special Conference on RAS Oncogenes: From Biology to Therapy; Feb 24-27, 2014; Lake Buena Vista, FL. Philadelphia (PA): AACR; Mol Cancer Res 2014;12(12 Suppl):Abstract nr A26. doi: 10.1158/1557-3125.RASONC14-A26
Abstract 4442: Inhibition of SIAH E3 ligase function leads to increased cell death in metastatic human cancer cells
Urban, Zena M., Reesema, Lauren van, Bian, Minglei, Smyrk, Thomas C. , Peterson, Gloria, Tang, Amy

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 4442-4442

10.1158/1538-7445.am2014-4442 Get It

Abstract Hyperactivation of the oncogenic K-RAS pathway leads to increased cell proliferation, tumor growth, and oxidative stress associated with increased ROS production, heightened mitochondrial bioenergetics, and altered cancer metabolisms. Downstream of the K-RAS pathway, Seven-In-Absentia human Homolog (SIAH) is required for proper ERBB/RAS signal transduction. Human peroxiredoxin (PRDX) is an antioxidant protein, whose precise role in modulating oxidative stress during oncogenesis remains to be elucidated. Increased levels of oxidative stress alter the bioenergetics and functional integrity of mitochondrial biology under cellular stress. This study aims to elucidate the biological interaction previously detected between PRDX and SIAH2 via biochemical assays. We plan to investigate the functional role of SIAH2-PRDX interaction in modulating the stress response and adaptive cell survival in K-RAS-driven tumors. Also, we would like to investigate the biological significance of SIAH2-PRDX interaction in response to increased cellular stress in K-RAS-driven human cancer cells treated with standard chemotherapies. Mitochondrial tracking (MITO-tracker®) was used to evaluate mitochondrial integrity of SIAH-proficient and SIAH-deficient human lung (A549) and cervical (HeLa) cancer cells over six days. Immunofluorescence staining and bright field imaging were performed using DOX-inducible human breast (MDA-MB231) and cervical (HeLa) cancer cells to compare changes in organelle integrity and mitochondrial morphology, altered expression of the oxidative stress biomarker and cell death biomarkers in response to induction of the SIAH- proficient and SIAH-deficient states in highly aggressive human cancer cells. By using human pancreatic cancer tissue microarrays (TMAs), we found that the antioxidant protein PRDX is significantly upregulated and co-expressed with SIAH in human pancreatic tumor biospecimens. It seems that PRDX is an indicative biomarker of cellular and oncogenic K-RAS-induced oxidative stress in human pancreatic cancer. By blocking SIAH2 function downstream of the K-RAS signaling pathway, oxidative stress levels were markedly increased, evidenced by mitochondrial aggregations and dysfunction in both human lung and cervical cancer cells. In response to anti-SIAH2 therapy, human TNBC, NSCLC and cervical cancer cells underwent dramatic morphological changes due to the significant loss of cell junction, focal adhesion and cell attachment. These data have shown that anti-SIAH2-based anti-K-RAS and anticancer therapy is highly effective in inducing massive cell death in several highly invasive and metastatic cancer lines. Further investigation into the molecular mechanisms of anti-SIAH2-induced cellular stress and cell death may contribute to the future drug development and validation of a new and effective anti-SIAH2-based targeted therapy against metastatic human cancer in the future. Citation Format: Zena M. Urban, Lauren van Reesema, Minglei Bian, Thomas C. Smyrk, Gloria Peterson, Amy H. Tang. Inhibition of SIAH E3 ligase function leads to increased cell death in metastatic human cancer cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4442. doi:10.1158/1538-7445.AM2014-4442